Compare AJANTA PHARMA with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ABBOTT INDIA AJANTA PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 23.2 42.8 54.3% View Chart
P/BV x 4.1 12.3 33.4% View Chart
Dividend Yield % 0.9 0.6 152.9%  

Financials

 AJANTA PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
ABBOTT INDIA
Mar-18
AJANTA PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,4226,110 23.3%   
Low Rs8983,996 22.5%   
Sales per share (Unadj.) Rs233.51,552.2 15.0%  
Earnings per share (Unadj.) Rs44.0188.8 23.3%  
Cash flow per share (Unadj.) Rs52.2196.4 26.6%  
Dividends per share (Unadj.) Rs9.0055.00 16.4%  
Dividend yield (eoy) %0.81.1 71.3%  
Book value per share (Unadj.) Rs255.1796.6 32.0%  
Shares outstanding (eoy) m88.0221.25 414.2%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.03.3 152.6%   
Avg P/E ratio x26.426.8 98.6%  
P/CF ratio (eoy) x22.225.7 86.4%  
Price / Book Value ratio x4.56.3 71.7%  
Dividend payout %20.529.1 70.3%   
Avg Mkt Cap Rs m102,081107,376 95.1%   
No. of employees `0006.83.3 204.7%   
Total wages/salary Rs m4,3073,937 109.4%   
Avg. sales/employee Rs Th3,022.69,929.3 30.4%   
Avg. wages/employee Rs Th633.41,185.1 53.4%   
Avg. net profit/employee Rs Th569.11,207.7 47.1%   
INCOME DATA
Net Sales Rs m20,55432,985 62.3%  
Other income Rs m2111,170 18.0%   
Total revenues Rs m20,76534,155 60.8%   
Gross profit Rs m5,6645,245 108.0%  
Depreciation Rs m721162 445.2%   
Interest Rs m1238 30.4%   
Profit before tax Rs m5,1436,215 82.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2732,203 57.8%   
Profit after tax Rs m3,8704,012 96.5%  
Gross profit margin %27.615.9 173.3%  
Effective tax rate %24.835.4 69.8%   
Net profit margin %18.812.2 154.8%  
BALANCE SHEET DATA
Current assets Rs m11,81222,655 52.1%   
Current liabilities Rs m3,7766,681 56.5%   
Net working cap to sales %39.148.4 80.7%  
Current ratio x3.13.4 92.2%  
Inventory Days Days7765 119.5%  
Debtors Days Days8229 279.9%  
Net fixed assets Rs m14,398835 1,723.4%   
Share capital Rs m175213 82.5%   
"Free" reserves Rs m22,27716,715 133.3%   
Net worth Rs m22,45216,928 132.6%   
Long term debt Rs m70-   
Total assets Rs m26,96224,162 111.6%  
Interest coverage x444.3163.7 271.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.81.4 55.8%   
Return on assets %14.416.8 85.9%  
Return on equity %17.223.7 72.7%  
Return on capital %23.036.9 62.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,682369 2,898.4%   
Fx outflow Rs m2,1023,807 55.2%   
Net fx Rs m8,580-3,438 -249.6%   
CASH FLOW
From Operations Rs m3,7481,527 245.4%  
From Investments Rs m-2,228-2,148 103.7%  
From Financial Activity Rs m-1,475-1,024 144.0%  
Net Cashflow Rs m45-1,646 -2.7%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 7.9 19.6%  
FIIs % 7.6 0.1 7,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 17.1 99.4%  
Shareholders   20,968 18,270 114.8%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  DIVIS LABORATORIES  ALEMBIC LTD  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, Developments From the IPO Space, and Top Cues in Focus Today(Pre-Open)

On Tuesday, Indian share markets fell sharply during closing hours amid fears of rising crude oil prices and weakness in the rupee.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 17, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS